Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial

Author(s): Mina S. Sedrak, MD, MS^1,2; Can-Lan Sun, PhD^1,3; Jingran Ji, MD²; Harvey J. Cohen, MD⁴; Cary P. Gross, MD⁵; William P. Tew, MD⁶; Heidi D. Klepin, MD, MS⁷; Tanya M. Wildes, MD, MS⁸; Efrat Dotan, MD⁹; Rachel A. Freedman, MD, MPH¹⁰; Tracey O’Connor, MD¹¹; Selina Chow, MD¹²; Mary Ann Fenton, MD¹³; Beverly Moy, MD, MPH¹⁴; Andrew E. Chapman, DO¹⁵; William Dale, MD, PhD^1,3; Vani Katheria, BS^1,3; Nicole M. Kuderer, MD¹⁶; Gary H. Lyman, MD, MPH¹⁷; Allison Magnuson, DO¹⁸; and Hyman B. Muss, MD¹⁹

Source: DOI: 10.1200/JCO.22.01440 Journal of Clinical Oncology

Dr. Anjan Patel's Thoughts

This study nicely confirms that older patients who are given lower doses or have treatment delays receive a lower benefit from adjuvant chemotherapy and have worse outcomes. About 20% of patients were given a low relative dose intensity overall. Of course, there may be other variables at play, but this highlights the need for early identification of patients who would benefit from aggressive supportive measures.

PURPOSE

Older women with high-risk early breast cancer (EBC) benefit from adjuvant chemotherapy, but their treatment is frequently complicated by toxic side effects, resulting in dose reductions and delays. This makes it challenging for oncologists to maintain a relative dose intensity (RDI) ≥ 85%, as recommended for optimal curative-intent treatment. Understanding which women are at risk of receiving suboptimal RDI may inform treatment discussions and guide early, targeted supportive care or geriatric comanagement interventions.

METHODS

This was a prespecified secondary analysis of the HOPE trial, which enrolled women age ≥ 65 years with EBC initiating neoadjuvant or adjuvant chemotherapy. RDI was calculated as the ratio of delivered to planned chemotherapy dose intensity. The primary outcome was low RDI, defined as RDI < 85%. Multivariable logistic regression with stepwise selection was used to evaluate the association between baseline variables (demographic, clinical, and geriatric assessment) and low RDI. Survival probability was estimated using the Kaplan-Meier method, and the log-rank test was used to compare overall survival.

RESULTS

Three hundred twenty-two patients (median age at diagnosis, 70 years; range, 65-86 years) were included. The median follow-up was 4 years. Sixty-six patients (21%) had a low RDI. Age ≥ 76 years (odds ratio [OR], 2.57; 95% CI, 1.12 to 5.91; P = .03), lower performance status (OR, 4.32; 95% CI, 1.98 to 9.42; P < .001), and use of anthracycline-based or cyclophosphamide, methotrexate, and fluorouracil regimens (OR, 3.47; 95% CI, 1.71 to 7.05; P < .001) were associated with low RDI. The 5-year overall survival probability was 0.80 versus 0.91 in patients with RDI < 85 versus ≥ 85%, respectively (log-rank P = .02).

CONCLUSION

One in five older patients with EBC treated with standard chemotherapy received low RDI and had inferior survival outcomes. Older patients at risk for low RDI should be identified and targeted upfront before initiating chemotherapy.

Author Affiliations

¹Center for Cancer and Aging, City of Hope, Duarte, CA ²Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA ³Department of Supportive Care Medicine, City of Hope, Duarte, CA ⁴Department of Medicine, Duke University School of Medicine, Durham, NC ⁵Department of Medicine, Yale School of Medicine, New Haven, CT ⁶Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY ⁷Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC ⁸Department of Medical Oncology, Nebraska Medicine, Omaha, NE ⁹Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA ¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA ¹¹Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY ¹²Department of Medicine, University of Chicago, Chicago, IL ¹³Department of Medicine, Brown University, Providence, RI ¹⁴Department of Medicine, Massachusetts General Hospital, Boston, MA ¹⁵Department of Medical Oncology, Sidney Kimmel Cancer Center/Jefferson Health, Philadelphia, PA ¹⁶Advanced Cancer Research Group, Kirkland, WA ¹⁷Department of Medicine, University of Washington, Seattle, WA ¹⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY ¹⁹Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

This is impressive. However, there is no reported placebo trastuzumab deruxtecan arm, so this is not truly a “no chemotherapy” regimen. It is important to remember that deruxtecan is itself a chemotherapy agent. So, this is really comparing deruxtecan vs taxol or more accurately, a comparison of chemotherapy delivery systems.

Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial

The QUIWI study used quizartinib, a FLT3 drug added to standard chemo induction/consolidation in FLT-negative acute myeloid leukemia (AML) patients. There was a meaningful overall survival (OS) improvement across all age and risk groups including the NPM1+ population. They purposefully used a higher dose to achieve what is felt to be off-target TKI activity in familiar pathways of KIT, PDGRF…etc.

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

This really feels like a first-line practice changer in PD-L1+ MTNBC—the sacituzumab govitecan/pembrolizumab combination delivering a 3.4-month progression-free survival (PFS) improvement and pushing median PFS past 11 months is quite meaningful. Mature overall survival (OS) data will be interesting to see. Remember to watch closely and consider screening for drug-induced interstitial lung disease(ILD).

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

ASCENT-03 shows that in first-line, PD-1/PD-L1–ineligible advanced TNBC, sacituzumab improves PFS to 9.7 vs 6.9 months and extends median duration of response (DOR) to 12.2 vs 7.2 months, with similar overall response rate (ORR) (48% vs 46%) and immature overall survival (OS) (21.5 vs 20.2 months) Grade ≥3. Adverse events (AEs) were comparable (66% vs 62%), but sacituzumab had more neutropenia and diarrhea, fewer discontinuations (4% vs 12%), and early-cycle infection-related deaths in patients without primary G-CSF. For PD-1/PD-L1–ineligible mTNBC, SG offers more durable control than chemo with manageable myelosuppression — so consider SG first-line and start G-CSF early in higher-risk patients.

Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline

Guidelines for post-mastectomy radiation include patients who received neoadjuvant therapy, with or without residual disease after treatment. A good topic to review.